PK150 (Sorafenib Analog)
25 CHF CHF 25.00
AG-CR1-0162-M0011 mgCHF 25.00
AG-CR1-0162-M0055 mgCHF 50.00
AG-CR1-0162-M02525 mgCHF 135.00
|Synonyms||Antibiotic PK150; 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)urea|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO (25mg/ml).|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Analog of the anticancer drug sorafenib.
- PK150 is a potent antibiotic. It shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively.
- PK150 did not induce in vitro resistance and shows oral bioavailability and in vivo efficacy. The mode of action includes the interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltransferase and the stimulation of protein secretion by altering the activity of signal peptidase IB.
- Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms: P. Le, et al.; Nat. Chem. 12, 145 (2020)